Answers are grounded in this paper and cite their sources.
Slightly more than half of men diagnosed with de novo metastatic castration-sensitive prostate cancer and a life expectancy of at least 3 years received additions to standard ADT as recommended by national guidelines in 2019-2022 in Sweden. There was a 2-fold increase in use of these treatments during the study period; however, efforts to further increase adherence to guidelines are warranted.
No takes yet. Share an insight, caveat, or question.
Gedeborg et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: